

1 Healthcare worker risk of COVID-19: A 20-month analysis of protective
2 measures from vaccination and beyond

3
4 Short title: Protecting healthcare workers from SARS-COV2: a 20-month longitudinal analysis

5 Annalee Yassi^{1,2}, Stephen Barker¹, Karen Lockhart¹, Jennifer M. Grant^{2,3}, Arnold Ikedichi
6 Okpani^{1,2}, Stacy Sprague⁴, Muzimkhulu Zungu^{5,6}, Stan Lubin², Chad Kim Sing^{7,8}

7
8 ¹ School of Population and Public Health (SPPH), University of British Columbia (UBC),
9 Vancouver, British Columbia (BC), Canada

10 ² Physician Occupational Safety and Health, Vancouver Coastal Health (VCH), Vancouver, BC,
11 Canada

12 ³ Department of Pathology and Laboratory Medicine, Vancouver Coastal Health (VCH),
13 Vancouver, Canada

14 ⁴ Employee Safety, Health and Wellness, VCH

15 ⁵ National Institute for Occupational Health (NIOH), a division of National Health Laboratory
16 Service (NHLS), Johannesburg, South Africa

17 ⁶ School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa

18 ⁷ Medicine, Quality and Safety, VCH

19 ⁸ Department of Emergency Medicine, UBC

20
21
22 Corresponding author:
23 Dr. Annalee Yassi
24 430-2206 East Mall, UBC
25 Vancouver, BC, V6T 1Z3
26 Annalee.Yassi@ubc.ca
27

28 Word count: 3842

29

30 Abstract:

31 Background: As the COVID-19 pandemic continues and new variants such as Omicron emerge,
32 we aimed to re-evaluate vaccine effectiveness as well as impacts of rigorously implemented
33 infection control, public health and occupational health measures in protecting healthcare
34 workers (HCWs).

35 Methods: Following a cohort of 21,242 HCWs in Vancouver, British Columbia, Canada, for 20
36 months since the pandemic started, we used Cox regression and test-negative-design to examine
37 differences in SARS-COV-2 infection rates compared to community counterparts, and within the
38 HCW workforce, assessing the role of occupation, testing accessibility, vaccination rates, and
39 vaccine effectiveness over time.

40 Results: Nurses, allied health professionals and medical staff in this jurisdiction had a
41 significantly lower rate of infection compared to their age-group community counterparts, at
42 47.4, 41.8, and 55.3% reduction respectively; controlling for vaccine-attributable reductions, the
43 protective impact was still substantial, at 33.4, 28.0, and 36.5% respectively. Licensed practical
44 nurses and care aides had the highest risk of infection among HCWs, more than double that of
45 medical staff. However, even considering differences in vaccination rates, no increase in SARS-
46 CoV-2 infection was found compared to community rates, with combined protective measures
47 beyond vaccination associated with a 17.7% reduced SARS-COV-2 rate in the VCH workforce
48 overall. There was also no evidence of waning immunity within at least 200 days after second
49 dose.

50 Conclusion: Rigorously implemented occupational health, public health and infection control
51 measures results in a well-protected healthcare workforce with infection rates at or below rates in

52 community counterparts. Greater accessibility of vaccination worldwide is essential; however, as
53 implementing measures to protect this workforce globally also requires considerable health
54 system strengthening in many jurisdictions, we caution against overly focusing on vaccination to
55 the exclusion of other crucial elements for wider protection of HCWs, especially in facing
56 ongoing mutations which may escape current vaccines.

57 **Keywords:**

58 healthcare workers; COVID-19; occupational health; infection control; public health; vaccine
59 effectiveness

60 Healthcare worker risk of COVID-19: A 20-month analysis of protective 61 measures from vaccination and beyond

62 *Health and care workers are the foundation of health systems and the driving force to achieving*
63 *universal health coverage and global health security. ...However, too many of them have become*
64 *infected, ill or died as a result of COVID-19.... These deaths are a tragic loss. They are also an*
65 *irreplaceable gap in the world's pandemic response...the world cannot be complacent.*

66
67 World Health Organization Steering Committee for the
68 International Year of Health and Care Workers in 2021 (1)

69

70 **Introduction:**

71 Healthcare workers (HCWs) continue to endure much stress while the COVID-19 pandemic
72 rages and new variants emerge, including Omicron, creating considerable new uncertainty (2).
73 HCWs are known to be at risk of occupational exposure to Severe Acute Respiratory Syndrome
74 coronavirus 2 (SARS-CoV-2 infection), if not adequately protected (3-9). Many experts believe
75 that community exposure, as opposed to occupational risk factors, are the main causes of
76 COVID-19 in HCWs (10, 11), and, in some jurisdictions, strong occupational health practices,
77 such as ready access and well-communicated guidance on use of personal protective equipment
78 (PPE), along with physical distancing, contact tracing and isolation requirements, have
79 converged to keep the healthcare workforce safe at work (12). Nonetheless, the inability to
80 “physically distance” at work in occupational groups such as flight attendants, hairdressers, and
81 food/agriculture workers have increased risk of occupational exposure to SARS-CoV-2 infection

82 (13-15). This is the case as well for frontline care workers in the long-term care (LTC) sector
83 who also have shown a higher risk of SARS-CoV-2 infection (12, 16). In Canada, LTC has been
84 disproportionately affected by the pandemic (17), and while there have been few COVID-19
85 deaths in HCWs across Canada, the rates of SARS-CoV-2 infection have been higher in licensed
86 practical nurses (LPNs) and care aides, than in other HCWs (12, 18).

87 The World Health Organization (WHO) designated 2021 the “International Year of Health and
88 Care Workers”, lamenting the estimated 115,500 COVID-19-related deaths among HCWs
89 worldwide (1, 19). Additionally, while vaccination of HCWs has been a key tool in the arsenal of
90 measures to protect the healthcare workforce (12, 20-23), the WHO noted that “available data
91 from 119 countries suggest that by September 2021, an average of only 40% of health and care
92 workers were fully vaccinated, with considerable difference across regions and economic
93 groupings. Less than 1 in 10 had been fully vaccinated in the African region, while 22 mostly
94 high-income countries reported that above 80% of their personnel were fully vaccinated.” (1).
95 As such, the emergence of a new variant, Omicron, is particularly worrisome.

96 The infection prevention and control (IPAC), as well as occupational health and public health
97 measures adopted in Vancouver, British Columbia, Canada, were described elsewhere (12).
98 HCWs were required to wear a medical mask (ASTM level 1, 2 or 3), eye protection and gloves
99 for all direct patient care, in addition to droplet and contact precautions when within 2 meters of
100 COVID-19 suspect or confirmed patients. N95 or equivalent respirators were permitted based on
101 a HCW’s point-of-care risk assessment (PCRA) and required when aerosol generating medical
102 procedures (AGMP) were performed on a positive or suspected COVID-19 patient. Cloth and
103 other non-approved masks were not permitted and double masking was strongly discouraged.

104 Physical distancing and capacity limits were created in staff common spaces and were supported
105 by occupational health teams throughout the pandemic. IPAC measures were communicated
106 regularly. Immunizations against COVID-19 began in December 2020, first for LTC staff,
107 residents and essential visitors, followed by highest risk acute HCWs (Emergency room,
108 Intensive care unit and COVID medical unit staff). Initially dose 2 was given 35 days after dose
109 1. The inter-dose interval was lengthened to 42 days in February 2020 then to 4 months (16
110 weeks) in early March 2021 to protect more people from severe disease and death (24) when
111 vaccine supply was limited. Virtually all HCWs were vaccinated with either the Pfizer-
112 BioNTech (93.3%) or Moderna (6.6%) COVID-19 vaccine (mRNA-1273). Vaccination of the
113 general public started in February 2021.

114 In this global context, now twenty months into the pandemic and with new concerns about the
115 sustained effectiveness of vaccines, we aimed to ascertain the ongoing effectiveness of the
116 current package of infection control, public health and occupational health measures in a
117 jurisdiction that has devoted considerable effort to protecting its healthcare workforce, including
118 recently mandating full vaccination for all HCWs. As there has been considerable controversy
119 about the effectiveness of dose schedules and vaccine program overalls, including the issue of
120 mandating vaccination for all HCWs with its concomitant risk of losing unvaccinated HCWs
121 from the workforce, we also aimed to explore the role of vaccination within this workforce to
122 help tease out the extent to which COVID-19 rates in this occupational group are impacted by
123 their higher rate of vaccination compared to the general population. Our goal in the present study
124 was, therefore, to document SARS-CoV-2 infection rates in HCWs, ascertaining the impact of
125 occupational role within the healthcare system on risk levels, taking community of residence and
126 vaccination rates into account, as well as the effectiveness of the vaccination strategy to date.

127 Methods

128 This observational cohort study was conducted among HCWs who provide services at the
129 Vancouver Coastal Health (VCH) region, one of five health regions in British Columbia (BC),
130 Canada. VCH provides acute, community and long-term care services to 1.25 million people
131 which constitutes about a quarter of the population of the province. VCH is the main advanced
132 health care referral region for the province. The VCH healthcare workforce includes 21,242
133 healthcare workers who provide services at 112 facilities (25).

134 For this study, we accessed the SARS-CoV-2 test records of all VCH HCWs who were tested
135 between March 1, 2020, and November 11, 2021. We also obtained COVID-19 vaccination
136 records for each HCW. Records were obtained from the provincial Workplace Health Indicator
137 Tracking and Evaluation (WHITE™) database which is used for a variety of occupational health
138 surveillance activities in the province. In addition to test (date and result) and vaccination
139 (vaccine type and date received) records, we extracted details on HCW demographics and
140 occupation including age group, sex, first 3 digits of the home residence postal code, worksite,
141 sector, job designation, and hours worked during the period of interest. We reclassified the more
142 than 1,000 occupational designations into seven categories: nurses, licensed practical nurses
143 (LPNs)/care aides, administration, allied health, medical staff, support staff, others/unknown.
144 Age groups were defined as 18-49, 50-59 and 60+. Home residence postal codes were mapped
145 to the two local health regions: VCH and Fraser Health (FH). Data on infection and vaccination
146 in the community were obtained from the BC Centre for Disease Control, with population
147 projections from Statistics Canada (26). Vaccination status was categorised as unvaccinated, first
148 dose, and second dose. We defined HCWs broadly to include anyone in any role

149 employed/contracted by VCH who provided in-person service at VCH or in homes or
150 community during the study period.

151 To avoid the possibility of reidentification of HCWs, prior to data extraction and analyses, each
152 HCWs was assigned a unique code known only to the team statistician. No personal identifying
153 information was included in the analytic dataset. This study was covered by the University of
154 British Columbia Behavioural Ethics Review Board approval, certificate number H21-01138.

155 [Statistical analysis](#)

156 Our outcome of interest was polymerase chain reaction (PCR)-confirmed SARS-CoV-2 from
157 nucleic acid amplification test on nasal swab or gargle samples. We explored multiple exposures
158 including occupation, home health authority (derived from postcodes), and vaccination status.
159 We plotted the SARS-CoV-2 infection rate (per 100,000 population) and test positivity (percent
160 of all tests performed that are positive) over time as a 7-day moving average for both HCWs and
161 the background community from March 1, 2020, to November 11, 2021. The background
162 community infection rates were both region and age-adjusted by weighting positive cases to
163 match the residence and age-range distribution of the workforce. We further summarized the
164 cumulative infection rate and vaccination status of HCWs, stratified by occupation, at the end of
165 the observation period on November 11, 2021. To estimate vaccine effectiveness among HCWs,
166 we first plotted the cumulative incidence of SARS-CoV-2 infection as an inverse Kaplan-Meier
167 plot, stratified by vaccination status, starting from January 24, 2021. Then, using a Cox-
168 proportional hazard regression model (27-30), we estimated the relative hazard ratio of one and
169 two doses of vaccine (with unvaccinated as the reference class), adjusted for pandemic week (epi
170 week), age group and residence. Vaccine effectiveness was calculated as 1 minus the hazard
171 ratio determined in the Cox regression model. For comparison, we used the test-negative-design

172 (TND) method (31-34) to estimate vaccine effectiveness, adjusting for pandemic week (epi
173 week), age group. We explored the difference in vaccine effectiveness by the interval between
174 the first and the second doses (less than six weeks versus more than six weeks between doses)
175 using the TND method, and further summarised test positivity by the date of the first dose (first
176 dose before March 1, 2021, versus on, or after, March 1, 2021). To calculate the relative risk of
177 HCWs compared to the background community, a logistic regression model was used to
178 determine the odds ratio. All test results from VCH and FH were included (both positive cases
179 and negative controls from HCWs and the background community), with the region and
180 pandemic week (epi week) of the test. We also adjusted for two-dose vaccination status;
181 however, while vaccination status of the HCWs at the time of the test was known, the
182 vaccination status was not published for community tests. Therefore, vaccination status for each
183 test was included as the likelihood of vaccination (0-100%), using the region-specific two-dose
184 community vaccination rate on the day of the test for community tests, 0% for tests on
185 unvaccinated HCWs, 100% for tests on HCWs with two doses. Test positivity was stratified by
186 residence and occupation, and significant differences in test positivity between strata were
187 detected using a chi-squared test. All analyses we conducted in R version 4.1.2 (35).

188 Results:

189 Figure 1 shows the infection rate of the VCH healthcare workforce as a whole throughout the
190 various phases of the pandemic, as well as their vaccination rates over time, along with the
191 comparable rates in their background communities of residence, adjusting for age-differences. It
192 could be seen that there was a spike of HCW infections at the beginning of the pandemic – likely
193 a combination of the fact that HCWs had much better access to testing compared to the general
194 community and consistent guidance on precautions and access to PPE. A small peak was also

195 seen in the second wave, possibly due to outbreaks which were associated with intensive case
196 findings efforts in HCWs, including asymptomatic testing – something not widely available for
197 the general public. We can see that during the third wave, HCWs were well-protected, as, by this
198 point, vaccination rates had been mounting. As for the peak in the fourth wave, this is examined
199 in more detail below.

200 Insert Figure 1 - Rate of PCR-confirmed SARS-COV2 infection and vaccination rates in VCH
201 healthcare workers and the community over time (March 1, 2020 - November 11, 2021)

202 Figure 2 parallels Figure 1 but shows positivity rate among those tested rather than incidence, to
203 better account for the greater likelihood of testing among HCWs. We see that the peak that was
204 seen in the healthcare workforce in the first wave in Figure 1, relative to the community, is no
205 longer evident. The peak in the fourth wave, however, is more pronounced, as explored further
206 below.

207 Insert Figure 2 – Rate of positive PCR-confirmed SARS COv2 infection amongst all VCH
208 healthcare workers tested, and vaccination rates, along with community comparison rates., over
209 time (March 1, 2020 - November 11, 2021)

210 Table 1 shows the COVID-19 overall infection rate and vaccination rate from the start of the
211 pandemic until November 11, 2021, by occupation. It can be seen that LPNs/care aides had
212 more than double the rate of infections as medical staff; we also see that a lower proportion of
213 LPNs/cade aides had been vaccinated.

214

215 Table 1. SARS-COV2 PCR-confirmed tests, and vaccination status by occupational group of
 216 VCH healthcare workers

	Tested positive for SARS-CoV-2		Fully vaccinated		Partially vaccinated		Unvaccinated		Total
	n	%	n	%	n	%	n	%	n
LPNs / care aides	170	5.9	2,841	97.9	18	0.6	43	1.5	2,902
Nurses	249	4.0	6,074	98.5	26	0.4	66	1.1	6,166
Allied health	95	3.0	3,073	98.6	17	0.5	27	0.9	3,117
Administration	214	4.3	4,863	97.8	40	0.8	68	1.4	4,971
Support staff	29	4.4	630	95.9	9	1.4	18	2.7	657
Medical staff	82	2.5	3,293	99.0	8	0.2	25	0.8	3,326
Other / unknown	17	3.8	435	98.2	4	0.9	4	0.9	443
Total	840	4	20,879	98.3	121	0.6	248	1.2	21,248

217

218 For analyses of the impact of vaccination on SARS-CoV-2 infection risk, we only considered the
 219 period January 24 to November 11th, 2021 as the numbers fully vaccinated before that date were
 220 too low to consider. First, we ascertained that of the 0.99 million unvaccinated person-days
 221 under observation within the healthcare cohort, there were 122 COVID-19 infections; for those
 222 partially vaccinated, there were 1.12 million person-days under observation, with 88 COVID-19
 223 infections; and for the fully vaccinated 3.48 million person-days, there were 136 COVID-19
 224 infections documented.

225 Using Cox regression, we found that the vaccine effectiveness (VE) of two doses, adjusted for
 226 epi-week, was 74.3% (62.8% to 82.2%). Adjusting for epi-week, age and gender, the VE was
 227 74.1% (62.5% to 82.1%). Figure 3 shows the cumulative incidence of SARS-CoV-2 infection in
 228 the workforce by vaccine status, over time. It can be seen that HCWs who were double-
 229 vaccinated had a much lower incidence rate of SARS-CoV-2 infections, with those partially
 230 vaccinated somewhere in between unvaccinated and fully vaccinated, as would be expected. It
 231 can also be seen that the curve for those double-vaccinated does not start increasing until over
 232 200 days post second dose, suggesting that the need for a booster dose does not appear to be

233 urgent in this cohort; however, by 224 days post-vaccination, the curve does start increasing
234 more sharply. Using the test-negative-design method, we considered the 6,177 tests of staff who
235 had had 2 doses of vaccine (140 positive; 2.3% test positivity); 2,697 tests of staff with 1 dose
236 (95 positive; 3.5% test positivity); 1,559 tests of unvaccinated staff (97 positive; 6.2% test
237 positivity) for a total of 10,473 tests. We see the unadjusted vaccine effectiveness (VE) is 65.0%
238 (95% CI 54.4, 73.2%). Adjusted for epi-week, we see an 82.8% (95% CI 73.9, 88.6%) rate
239 reduction, and adjusted for epi-week, age and gender, this is still 82.8% (95% CI 74.0, 88.6%),
240 as age and gender did not prove to be a significant covariate within our data.

241 Insert Figure 3 – Cumulative incidence of PCR-confirmed SARS-COV2 over time in VCH
242 healthcare workers January 24-November 11, by vaccination status

243 Revisiting the differing COVID-19 rates in each of the occupational groups (shown previously in
244 Table 1) adjusting now for the differing community rates in the areas in which they live and the
245 calendar week of the test, it can be seen from Column 2 of Table 2 that for LPNs/care aides, the
246 rate of COVID-19 infection was 10% lower than their background community but with a wide
247 confidence interval such that this difference is not significant. In contrast, for nurses, allied
248 health professionals and medical staff, the lower rate compared to their communities of residence
249 was indeed significant, with the reductions substantial, at 47.4%, 41.8%, and 55.3% respectively.
250 When the differences in vaccination rates between HCWs and their communities of residence are
251 taken into consideration, the difference in COVID-19 rates were 33.4%, 28.0 % and 36.5%
252 lower, respectively. In other words, medical staff had a 55.3% reduction in their risk of COVID-
253 19 compared to their community COVID-19 rates; further adjusting for vaccine uptake, medical
254 staff showed a 36.5% reduction in risk of COVID-19 compared to others in their communities.
255 Overall, we see that HCWs have lower odds of testing positive than their community

256 counterparts, with 35.4% (95% CI 27.8, 42.3%) lower risk for HCWs when controlling for
 257 calendar time and region and 17.7% (95% CI 7.6, 26.8%) lower risk for HCWs when further
 258 controlling for vaccine uptake.

259 Table 2. COVID-19 risk reduction by occupational group within VCH healthcare workers
 260 compared to community of residence and adjusted by vaccine status

Occupation (n = number of PCR tests)	Adjusting for epi-week and health region of residence			Adjusting for epi-week, health region of residence and vaccine status		
	1 – Odds Ratio	95% CI	P value	1 – Odds Ratio	95% CI	P value
LPNs / care aides	10.7%	-11.4%, 28.3%	0.317	-24.5%	-56.1%, 0.7%	0.057
Nurses	47.4%	35.3%, 57.2%	<0.001	33.4%	17.9%, 46.0%	<0.001
Allied health	41.8%	21.6%, 56.8%	<0.001	28.0%	2.7%, 46.7%	0.032
Administration	13.3%	-12.2%, 33.1%	0.278	2.1%	-26.9%, 24.6%	0.87
Support staff	8.9%	-86.2%, 55.4%	0.798	-1.0%	-107.1%, 50.7%	0.979
Medical staff	55.3%	35.0%, 69.3%	<0.001	36.5%	7.2%, 56.6%	0.019
Overall	35.4%	27.8%, 42.3%	<0.001	17.7%	7.6%, 26.8%	<0.001

261

262 Finally, we returned to examine the COVID-19 peak in the 4th wave in HCWs to see what might
 263 account for this. We found that in the 9 weeks beginning August 29, 2021 (epi weeks 35-43), as
 264 shown in Table 3, we saw a higher test positivity rate in HCWs than the community, as 2,890
 265 HCWs had been tested, with 106 testing positive (3.7%) over this period, while 581,385 tests
 266 were done on their community counterparts with 17,030 positive cases (2.9%). We found that the
 267 majority (97.7%) of tests performed on HCWs were on fully vaccinated HCWs (at least 1 week
 268 after the second vaccine), so it was no surprise that 98 of the 106 COVID-19 cases in HCWs
 269 were in those fully vaccinated (“breakthrough cases”). Those who were not fully vaccinated,
 270 however, had a positivity rate of 9.8%, which drove up the positivity rate overall. What was
 271 noteworthy in our refined analysis, however, was that, again, the group with the highest COVID-
 272 19 positivity was LPN/care aides, accounting for 31 of the cases during the period, with
 273 positivity of 7.5%. One of our hypotheses was that these individuals may have been HCWs who

274 were vaccinated early and had a shorter interval between first and second dose. Indeed, as shown
 275 in Table 4, this seems to be the case; those who had been vaccinated early, with only 6 weeks
 276 between doses, had a significantly higher positivity rate than those vaccinated later and/or with a
 277 longer interval between doses.

278 Table 3. SARS-COV2 PCR-confirmed results for Vancouver Coastal Health community, Fraser
 279 Health community and VCH healthcare worker occupational groups during the 4th wave (August
 280 29-October 30, 2021)

Category	Positive tests (n)	Negative tests (n)	Total tests (n)	Positivity (%)	P value
Overall					
HCWs	106	2,784	2,890	3.7%	0.022
Community	17,030	564,355	581,385	2.9%	0.022
HCW vaccine status					
Fully vaccinated	98	2,710	2,808	3.5%	0.009
Not fully vaccinated	8	76	82	9.8%	0.009
HCW home residence					
HCWs living in VCH	69	1971	2040	3.4%	0.286
HCWs living in FH	33	731	764	4.3%	0.286
HCW Occupation					
LPNs / care aides	31	384	415	7.5%	< 0.001
Nurses	41	849	890	4.6%	0.116
Allied health	9	500	509	1.8%	0.015
Administration	11	378	389	2.8%	0.389
Support staff	1	34	35	2.9%	1.000
Medical staff	13	595	608	2.1%	0.027

281

282 Table 4. SARS-COV2 PCR Confirmed test results in the 4th wave in full-vaccinated VCH
 283 HCWS by date of first dose and dose schedule

Dose schedule	First dose	Positive tests (n)	Negative tests (n)	Total tests (n)	Positivity (%)	P value
Less than 6 weeks between doses	First dose before March 1	30	524	554	5.4%	0.011
Less than 6 weeks between doses	First dose on or after March 1	1	21	22	4.5%	1.000
Over 6 weeks between doses	First dose before March 1	48	1415	1463	3.3%	0.487
Over 6 weeks between doses	First dose on or after March 1	19	706	725	2.6%	0.147
Overall		98	2,666	2,765	3.5%	0.045

284

285 Discussion

286 Throughout this pandemic, HCWs have, quite understandably, been concerned about their risks
287 of COVID-19 given the nature of their jobs. Worldwide this certainly merits further attention,
288 particularly as the pandemic is far from over and the risk of new variants, such as Omicron, is
289 ever present. However, what we have shown is that in a jurisdiction that has devoted
290 considerable effort to HCW protection, occupational risk can be kept to a minimum. In
291 jurisdictions where research was able to be done in this regard, studies have generally linked
292 HCW infection to community factors rather than to exposure in the occupational environment,
293 Previous analysis of the Vancouver HCW cohort (12), as well as research from other well-
294 resourced areas (36, 37), were in line with the analysis presented here: indeed VCH HCWs have
295 incurred significantly lower rates of SARS-COV-2 infection than those of the same age-group in
296 the communities in which they live.

297 However, we did find that LPNs and care aides, as well as support staff (which includes
298 housekeeping, laundry, food services, maintenance, trades, porters, and drivers), had higher rates
299 than other HCWs in our cohort. For these occupational groups, rates closely mirrored rates in the
300 communities in which they live (12, 18) where it is widely believed that a host of socioeconomic
301 factors converge to drive risk levels. These occupational groups are also comprised more often of
302 migrants and ethnic minorities known to be at higher risk due to a myriad of social determinants
303 (38). As adjusting for community rates and vaccine uptake did not result in the same level of
304 reduction seen for higher-income HCWs suggest that greater patient contact in combination with
305 perhaps less training and accessibility of resources, militates for even greater efforts to protect
306 this component of the workforce.

307 We showed that vaccination reduced the risk for HCWs beyond reductions from occupational,
308 infection control and other public health measures. Importantly, with a large proportion of the
309 world not yet vaccinated, and many other pressing needs for healthcare resources and world
310 attention (39, 40), our findings indicate that there does not appear to be an urgency for booster
311 doses among HCWs in this well-protected setting, although the trend toward waning immunity
312 from the vaccine does appear to be starting. It is also not yet known whether a booster is even
313 needed at this stage to protect against severe disease, which, after all, is the ultimate reason for
314 vaccination (41-43). Our data do, nonetheless, suggest that some portion of the infections in the
315 fourth wave may be due to HCWs having been vaccinated in the early days of vaccine
316 availability with closer dosing schedules, which may account for a higher rate of waning
317 immunity (44); this finding coheres with other studies suggesting the value of having had a
318 longer dose scheduling interval (45). In Israel, recent studies have shown that, despite high
319 vaccine coverage and effectiveness, the incidence of SARS-CoV-2 has been increasing (46);
320 Israel used a schedule that had the second dose administered 21 days after first dose (47). As
321 noted above, Canada proceeded with a longer interval between first and second dose, usually 16
322 weeks (48), except for high-risk HCWs who were vaccinated early and with a shorter dose
323 interval.

324 While we have shown that rigorous implementation of infection control, occupational health and
325 public health measures provide excellent protection, it is known that such measures are not fully
326 in place worldwide. Zungu and colleagues, for example, demonstrated the need for system
327 strengthening in hospitals across South Africa (49). Also Alhumaid et al. (50) documented that
328 compliance with infection control in healthcare is associated with non-availability of resources,
329 high workload and time limitation, as well as risk perception, caring for patients with history of

330 infectious disease. Thus, it is important to stress that the lack of increased risk for HCWs in VCH
331 should not be generalized to other jurisdictions where PPE and other infection control supplies
332 may not be as easily accessible to all HCWs, or staff shortages result in breaches in proper
333 protocols essential for staff and patient protection. Rather, the findings should provide
334 reassurance that when evidence-based policies and procedures are implemented, revised as
335 needed, with repeat educational messaging and rigorously monitored infection rates, this
336 crucially important workforce can indeed be protected.

337 [Concluding remarks](#)

338 As HCWs in this jurisdiction, and many others, face the choice of getting vaccinated or losing
339 their job, some HCWs have asked whether vaccinations really makes a difference to their
340 protection if they meticulously adhere to all other public health, occupational health and
341 infection control guidelines. Our findings from analyzing 20 months of HCW surveillance data
342 indeed reinforce the value of rigorous occupational health and infection control measures in
343 protecting HCWs from occupational exposures. Nonetheless, we have also shown that the
344 vaccination program for the VCH healthcare workforce has been very effective in lowering
345 HCW risk of COVID-19 beyond the combined occupational health, public health and infection
346 control measures implemented. And, of course, vaccination also protects against community
347 exposures, and from severe disease. As such, it can be stated that while HCWs *in this*
348 *jurisdiction* are not at increased risk of COVID-19 as a result of occupational exposures,
349 vaccination is not only of theoretical importance to decrease the risk of transmission to
350 vulnerable patients, but also is a measure that brings down risks for the workforce itself.

351 The issue of vaccination mandates is complex and subject to considerations outside the realm of
352 medicine. From a practical point of view, mandatory vaccination may be impossible to
353 implement due to HCW shortages, or because of philosophic objections or legal challenges. If
354 implemented there needs to be avenues for *bona fide* medical exemptions for those with
355 legitimate concerns, with adjudication by a neutral body with a worker-centred lens. Regardless
356 of how vaccination is encouraged, it is clear that the HCW population can be well protected at
357 work if rigorous occupational health and infection control measures are in place, and that
358 vaccination provides additional benefit to workers both at work and in the community.

359 As the 2021 WHO Call to Action noted, shortages of health and care workers are exacerbated by
360 the COVID-19 pandemic, with 66% of countries reporting health workforce shortages as the
361 primary cause of disruption to essential health services (1). We stress that ensuring accessible
362 programs of vaccination for HCWs is essential, and hoarding of vaccine by high-income
363 countries or blocking more ready access of lower income countries to vaccine production is to be
364 soundly opposed to ensure availability of vaccine for HCWs worldwide, the other measures that
365 protect HCWs more broadly must not fall out of the spotlight as this pandemic moves to new
366 stages. It must be kept in mind that HCWs face a myriad of risks, and as documented even before
367 the pandemic, HCWs face considerable psychological distress associated with working
368 conditions (51), with attention increasingly focused on the need for interventions to protect the
369 mental health of HCWs (52, 53). Since the pandemic began, as also noted by the WHO in
370 referring to the situation for HCWs globally, “levels of anxiety, distress, fatigue, occupational
371 burnout, stigmatization, physical and psychological violence have all increased significantly”
372 (1). Additionally, while SARS-COV2 is an immediate threat of occupational infectious
373 transmission to HCWs worldwide, other occupational respiratory diseases, including

374 tuberculosis, still account for high morbidity and mortality in HCWs on a global scale (54).

375 Thus, global policies, public attention and resource allocation must keep this in mind.

376 **Funding:**

377 This work was supported by The International Development Research Centre (IDRC) under

378 grant M20-00559, “Protecting healthcare workers from COVID-19: a comparative

379 contextualized analysis”. AY is supported as a Chair in Global Health from the Canada Research

380 Council. The funders had no role in study design, data collection and analysis, decision to

381 publish, or preparation of the manuscript.

382 **Acknowledgements:**

383 The authors wish to offer our gratitude to all the healthcare workers who have worked tirelessly

384 throughout the pandemic. We also thank the many University of British Columbia medical

385 students who staffed the Physician Occupational Safety and Health (POSH) service, as well as

386 the Infection Prevention and Control, Public Health and People Safety teams who all work

387 tirelessly to ensure that the healthcare workforce was well-protected. We thank the People

388 Analytics team who extracted the data we needed for this research and the Vancouver Coastal

389 Health staff who ensure excellent communications and a comprehensive database which guides

390 operations and facilitates research.

391 **Institutional ethics review:**

392 The study was conducted according to the guidelines of the Declaration of Helsinki, and

393 approved by the Institutional Review Board of the University of British Columbia (H21-01138).

394 **Data Availability Statement:**

395 The data underlying the results presented in the study are available from

396 <http://innovation.ghrp.ubc.ca/COVID19/data-2021.11.29.xlsx>

397 **Conflicts of Interest:**

398 AY, JG, SS, CKS, SL and AO are staff or contractors of Vancouver Coastal Health.

399 AO, KL and SB are paid on grant funds.

400 AY is partially paid from a research chair through the Canadian government.

401 **References:**

- 402 1. Members of the Steering Committee for the International Year of Health and Care
403 Workers. Joint statement of WHO's estimates of health and care worker deaths due to COVID-
404 19. available at [https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-](https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-during-covid-19)
405 [during-covid-19](https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-during-covid-19): WHO; 2021.
- 406 2. World Health Organization (WHO). Classification of Omicron (B.1.1.529): SARS-CoV-
407 2 Variant of Concern. Geneva: WHO; 26 November 2021. available at
408 [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
409 [variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern).
- 410 3. McEllistrem MC, Clancy CJ, Buehrle DJ, Singh N, Lucas A, Sirianni V, et al. SARS-
411 CoV-2 is associated with high viral loads in asymptomatic and recently symptomatic healthcare
412 workers. PLOS One. 2021;16(3):e0248347.
- 413 4. Boffetta P, Violante F, Durando P, De Palma G, Pira E, Vimercati L, et al. Determinants
414 of SARS-CoV-2 infection in Italian healthcare workers: a multicenter study. Sci Rep.
415 2021;11(1):1-8.
- 416 5. Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, et al. High SARS-CoV-2 antibody
417 prevalence among healthcare workers exposed to COVID-19 patients. J Infect. 2020;81(3):420-
418 6.

- 419 6. Alshamrani MM, El-Saed A, Al Zunitan M, Almulhem R, Almohrij S. Risk of COVID-
420 19 morbidity and mortality among healthcare workers working in a Large Tertiary Care Hospital.
421 *Int J Infect Dis.* 2021;109:238-43.
- 422 7. Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo C-G, Ma W, et al. Risk of COVID-
423 19 among front-line health-care workers and the general community: a prospective cohort study.
424 *Lancet Public Health.* 2020;5(9):e475-e83.
- 425 8. Naesens R, Mertes H, Clukers J, Herzog S, Brands C, Vets P, et al. SARS-CoV-2
426 seroprevalence survey among health care providers in a Belgian public multiple-site hospital.
427 *Epidemiol Infect.* 2021;149.
- 428 9. Mutambudzi M, Niedwiedz C, Macdonald EB, Leyland A, Mair F, Anderson J, et al.
429 Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank
430 participants. *Occup Environ Med.* 2021;78(5):307-14.
- 431 10. Baker JM, Nelson KN, Overton E, Lopman BA, Lash TL, Photakis M, et al.
432 Quantification of occupational and community risk factors for SARS-CoV-2 seropositivity
433 among health care workers in a large US health care system. *Ann Intern Med.* 2021;174(5):649-
434 54.
- 435 11. Jacob JT, Baker JM, Fridkin SK, Lopman BA, Steinberg JP, Christenson RH, et al. Risk
436 factors associated with SARS-CoV-2 seropositivity among US health care personnel. *JAMA*
437 *Netw Open.* 2021;4(3):e211283-e.
- 438 12. Yassi A, Grant JM, Lockhart K, Barker S, Sprague S, Okpani AI, et al. Infection control,
439 occupational and public health measures including mRNA-based vaccination against SARS-
440 CoV-2 infections to protect healthcare workers from variants of concern: a 14-month
441 observational study using surveillance data. *PLOS One.* 2021;July 16.

- 442 13. Chen Y-H, Glymour M, Riley A, Balmes J, Duchowny K, Harrison R, et al. Excess
443 mortality associated with the COVID-19 pandemic among Californians 18–65 years of age, by
444 occupational sector and occupation: March through November 2020. *PLOS One*.
445 2021;16(6):e0252454.
- 446 14. Fenton L, Gribben C, Caldwell D, Colville S, Bishop J, Reid M, et al. Risk of hospital
447 admission with covid-19 among teachers compared with healthcare workers and other adults of
448 working age in Scotland, March 2020 to July 2021: population based case-control study. *BMJ*.
449 2021;374.
- 450 15. Zhang M. Estimation of differential occupational risk of COVID-19 by comparing risk
451 factors with case data by occupational group. *Am J Ind Med*. 2021;64(1):39-47.
- 452 16. Greene J, Gibson DM. Workers at long-term care facilities and their risk for severe
453 COVID-19 illness. *Prev Med*. 2021;143:106328.
- 454 17. Canadian Institute for Health Information (CIHI). The Impact of COVID-19 on Long-
455 Term Care in Canada: Focus on the First 6 Months. Ottawa, ON: CIHI; 2021.
- 456 18. Okpani AI, Barker S, Lockhart K, Grant J, Delgado-Ron J, Zungu M, et al. A mixed-
457 methods study of risk factors and experiences of healthcare workers tested for the novel
458 coronavirus in Canada. *Occup Environ Med*. 2021, submitted November 2021.
- 459 19. World Health Organization (WHO). The impact of COVID-19 on health and care
460 workers: A closer look at deaths. Geneva: WHO; 2021.
- 461 20. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine
462 coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine
463 against infection (SIREN): a prospective, multicentre, cohort study. *Lancet*. 2021.


- 464 21. Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, et al. Effectiveness
465 of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare
466 personnel. Clin Infect Dis. 2021.
- 467 22. Brown K, Stall N, Vanniyasingam T. Early impact of Ontario's COVID-19 vaccine
468 rollout on long-term care home residents and health care workers. Science Briefs of the Ontario
469 COVID-19 Science Advisory Table. 2021;2:13.
- 470 23. Dunbar E, Godbout E, Pryor R, Rozycki HJ, Bearman G. Impact of coronavirus disease
471 2019 (COVID-19) vaccination program on healthcare worker infections in an academic hospital.
472 Infect Control Hosp Epidemiol. 2021;1-2.
- 473 24. National Advisory Committee on Immunization (NACI). Archived 5: NACI rapid
474 response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and
475 population protection in Canada [2021-03-03]. available at [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html)
476 [health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html)
477 [response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html);
478 2021.
- 479 25. Vancouver Coastal Health (VCH). About Us. available at <http://www.vch.ca/about-us>
480 2020.
- 481 26. Statistics Canada. Census Profile, 2016 Census - Northeast [Economic region], British
482 Columbia and British Columbia [Province] available at [https://www12.statcan.gc.ca/census-](https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=ER&Code1=5980&Geo2=PR&Code2=59&SearchText=Northeast&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=5980&TABID=1&type=02019)
483 [recensement/2016/dp-](https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=ER&Code1=5980&Geo2=PR&Code2=59&SearchText=Northeast&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=5980&TABID=1&type=02019)
484 [pd/prof/details/page.cfm?Lang=E&Geo1=ER&Code1=5980&Geo2=PR&Code2=59&SearchTex](https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=ER&Code1=5980&Geo2=PR&Code2=59&SearchText=Northeast&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=5980&TABID=1&type=02019)
485 [t=Northeast&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=5980&T](https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=ER&Code1=5980&Geo2=PR&Code2=59&SearchText=Northeast&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=5980&TABID=1&type=02019)
486 [ABID=1&type=02019](https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=ER&Code1=5980&Geo2=PR&Code2=59&SearchText=Northeast&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=5980&TABID=1&type=02019).

- 487 27. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings
488 from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in
489 Scotland: a national prospective cohort study. *Lancet*. 2021;397(10285):1646-57.
- 490 28. Glampson B, Brittain J, Kaura A, Mulla A, Mercuri L, Brett SJ, et al. Assessing COVID-
491 19 vaccine uptake and effectiveness through the North West London Vaccination Program:
492 retrospective cohort study. *JMIR Public Health Surveill*. 2021;7(9):e30010.
- 493 29. Azamgarhi T, Hodgkinson M, Shah A, Skinner JA, Hauptmannova I, Briggs TW, et al.
494 BNT162b2 vaccine uptake and effectiveness in UK healthcare workers—a single centre cohort
495 study. *Nat Commun*. 2021;12(1):1-6.
- 496 30. Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K, et al.
497 Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline
498 workers before and during B. 1.617. 2 (Delta) variant predominance—eight US locations,
499 December 2020–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(34):1167.
- 500 31. Thompson MG. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-
501 1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel,
502 First Responders, and Other Essential and Frontline Workers—Eight US Locations, December
503 2020–March 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70.
- 504 32. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al.
505 Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. *N Engl J Med*.
506 2021;385(15):1355-71.
- 507 33. Grannis SJ, Rowley EA, Ong TC, Stenehjem E, Klein NP, DeSilva MB, et al. Interim
508 estimates of COVID-19 vaccine effectiveness against COVID-19–associated emergency
509 department or urgent care clinic encounters and hospitalizations among adults during SARS-


- 510 CoV-2 B. 1.617. 2 (Delta) variant predominance—Nine States, June–August 2021. *MMWR*
511 *Morb Mortal Wkly Rep.*. 2021;70(37):1291.
- 512 34. Dean NE, Hogan JW, Schnitzer ME. Covid-19 vaccine effectiveness and the test-
513 negative design. *N Engl J Med.* 2021;385(October 7, 2021):15.
- 514 35. R Core Team. R: A language and environment for statistical computing. Vienna, Austria:
515 R Foundation for Statistical Computing; 2021.
- 516 36. Sikkema RS, Pas SD, Nieuwenhuijse DF, O'Toole Á, Verweij J, van der Linden A, et al.
517 COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-
518 sectional study. *Lancet Infect Dis.* 2020;20(11):1273-80.
- 519 37. Lan F-Y, Filler R, Mathew S, Buley J, Iliaki E, Bruno-Murtha LA, et al.
520 Sociodemographic risk factors for coronavirus disease 2019 (COVID-19) infection among
521 Massachusetts healthcare workers: A retrospective cohort study. *Infect Control Hosp Epidemiol.*
522 2021:1.
- 523 38. Morales DR, Ali SN. COVID-19 and disparities affecting ethnic minorities. *Lancet.*
524 2021;397(10286):1684-5.
- 525 39. Jensen N, Kelly A, Avendano M. The COVID-19 pandemic underscores the need for an
526 equity-focused global health agenda. *Humanit Soc Sci Commun.* 2021;8(1):1-6.
- 527 40. Peiris D, Sharma M, Praveen D, Bitton A, Bresick G, Coffman M, et al. Strengthening
528 primary health care in the COVID-19 era: a review of best practices to inform health system
529 responses in low-and middle-income countries. *WHO South East Asia J Public Health.*
530 2021;10(3):6.


- 531 41. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The
532 impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States.
533 Clin Infect Dis. 2021.
- 534 42. Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 patients requiring mechanical
535 ventilation following implementation of a national COVID-19 vaccination program—Israel,
536 December 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021;70(9):326.
- 537 43. Cook T, Roberts J. Impact of vaccination by priority group on UK deaths, hospital
538 admissions and intensive care admissions from COVID-19. Anaesthesia. 2021;76(5):608-16.
- 539 44. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al.
540 Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J
541 Med. 2021.
- 542 45. Carazo S, Talbot D, Boulianne N, Brisson M, Gilca R, Deceuninck G, et al. Single-Dose
543 Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome
544 Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative
545 Design From Québec, Canada. Clin Infect Dis. 2021; August 2021.
- 546 46. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune
547 humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021.
- 548 47. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA
549 Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-
550 23.
- 551 48. BC Centre for Disease Control (BCCDC). Public health statement on extension of the
552 interval between first and second doses of COVID-19 vaccines in BC. 24 June 2021.

- 553 49. Zungu M, Voyi K, Mlangeni N, Moodley SV, Ramodike J, Claassen N, et al.
554 Organizational factors associated with health worker protection during the COVID-19 pandemic
555 in four provinces of South Africa. *BMC Health Serv Res.* 2021;21(1):1-15.
- 556 50. Alhumaid S, Al Mutair A, Al Alawi Z, Alsuliman M, Ahmed GY, Rabaan AA, et al.
557 Knowledge of infection prevention and control among healthcare workers and factors
558 influencing compliance: a systematic review. *Antimicrobial Resistance & Infection Control.*
559 2021;10(1):1-32.
- 560 51. Kabito GG, Mekonnen TH. Psychological distress symptoms among healthcare
561 professionals are significantly influenced by psychosocial work context, Ethiopia: A cross-
562 sectional analysis. *PLOS One.* 2020;15(9):e0239346.
- 563 52. Gray P, Senabe S, Naicker N, Kgalamono S, Yassi A, Spiegel JM. Workplace-Based
564 Organizational Interventions Promoting Mental Health and Happiness among Healthcare
565 Workers: A Realist Review. *Int J Environ Res Public Health.* 2019;16(22):4396.
- 566 53. Thorn R. A call to action: Promoting mental wellbeing in South African healthcare
567 workers. *SAMJ: South African Medical Journal.* 2020;110(8):716.
- 568 54. Tudor C, Van der Walt ML, Margot B, Dorman SE, Pan WK, Yenokyan G, et al.
569 Occupational risk factors for tuberculosis among healthcare workers in KwaZulu-Natal, South
570 Africa. *Clin Infect Dis.* 2016;62(suppl_3):S255-S61.
- 571



- Healthcare worker cases
 - Community cases (regional age adjusted)
- Healthcare worker vaccination (≥ 2 doses)
 - Community vaccination (≥ 2 doses in eligible population)





— Unvaccinated
 — ≥14 days after dose 1
 — ≥7 days after dose 2

Number at risk at the time of observation

■	16133	13626	4916	2485	1769	1203	999	887	746	518	325
■	4566	4818	9627	11936	12288	7331	1344	513	350	336	215
■	4448	4448	6143	6194	6527	18602	18602	19144	19402	19598	19886